Results 31 to 40 of about 5,819 (161)

Clinical Features and Long-term Prognosis of Crohn’s Disease in Korea: Results from the Prospective CONNECT Study

Gut and Liver, 2022
Background/Aims: The prospective Crohn’s Disease Clinical Network and Cohort Study is a nationwide multicenter cohort study of patients with Crohn’s disease (CD) in Korea, aiming to prospectively investigate the clinical features and long-term prognosis ...
Seung Wook Hong, Byong Duk Ye, Jae Hee Cheon, Ji Hyun Lee, Ja Seol Koo, Byung Ik Jang, Kang-Moon Lee, You Sun Kim, Tae Oh Kim, Jong Pil Im, Geun Am Song, Sung-Ae Jung, Hyun Soo Kim, Dong Il Park, Hyun-Soo Kim, Kyu Chan Huh, Young-Ho Kim, Jae Myung Cha, Geom Seog Seo, Chang Hwan Choi, Hyun Joo Song, Gwang Ho Baik, Ji Won Kim, Sung Jae Shin, Young Sook Park, Chang Kyun Lee, Jun Lee, Sung Hee Jung, Yunho Jung, Sung Chul Park, Young-Eun Joo, Yoon Tae Jeen, Dong Soo Han, Suk-Kyun Yang, Hyo Jong Kim, Won Ho Kim, Joo Sung Kim   +36 more
doaj   +1 more source

Sustained Clinical Efficacy and Mucosal Healing of Thiopurine Maintenance Treatment in Ulcerative Colitis: A Real-Life Study

Gastroenterology Research and Practice, 2018
Background and Aims. Thiopurines are commonly used for treating ulcerative colitis (UC), despite the fact that controlled evidence supporting their efficacy is limited.
Daniela Pugliese, Annalisa Aratari, Stefano Festa, Pietro Manuel Ferraro, Rita Monterubbianesi, Luisa Guidi, Maria Lia Scribano, Claudio Papi, Alessandro Armuzzi   +8 more
doaj   +1 more source

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

British Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis, Leiah J. Brigitha, Lidwien M. Hanff, Alwin D. R. Huitema, Inge M. van der Sluis, Meta H. M. Diekstra   +5 more
wiley   +1 more source

The decline of 6‐thioguanine nucleotides is not linked to impaired efficacy or safety of thiopurines in pregnant women with inflammatory bowel disease

British Journal of Clinical Pharmacology, EarlyView.
Background Thiopurines are used to maintain remission in inflammatory bowel disease (IBD). These drugs are metabolized into 6‐thioguanine nucleotides (6‐TGN), associated with efficacy, and 6‐methylmercaptopurine ribonucleotides (6‐MMPR), associated with adverse drug reactions. Pregnancy has been linked to a shift in thiopurine metabolism, characterized
Dianne G. Bouwknegt, Paola Mian, Femke Groen, Denise van den Berg‐Zuiddam, Andrea E. van der Meulen, Femke Crouwel, Nanne K. de Boer, Debbie S. Deben, Dennis R. Wong, Luc J. J. Derijks, Gerard Dijkstra, Arno R. Bourgonje, C. Janneke van der Woude, Marijn C. Visschedijk   +13 more
wiley   +1 more source

Thiopurines: Recent Topics and Their Role in the Treatment of Inflammatory Bowel Diseases

Frontiers in Pharmacology, 2021
Ulcerative colitis (UC) and Crohn's disease (CD) are chronic inflammatory bowel diseases (IBD) of unknown etiology, characterized by repeated relapse and remission. The efficacy of thiopurine in IBD was first reported in the late 1960s.
Keiichi Tominaga, Takeshi Sugaya, Takanao Tanaka, Mimari Kanazawa, Makoto Iijima, Atsushi Irisawa   +5 more
doaj   +1 more source

Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing [PDF]

Clinical Pharmacology & Therapeutics, 2011
Thiopurine methyltransferase (TPMT) activity exhibits monogenic co-dominant inheritance, with ethnic differences in the frequency of occurrence of variant alleles. With conventional thiopurine doses, homozygous TPMT-deficient patients (~1 in 178 to 1 in 3,736 individuals with two nonfunctional TPMT alleles) experience severe myelosuppression, 30-60% of
Relling, M V, Gardner, E E, Sandborn, W J, Schmiegelow, K, Pui, C-H, Yee, S W, Stein, Paul C., Carrillo, Maria Berrocal, Evans, W E, Klein, T E   +9 more
openaire   +3 more sources

Concomitant 5‐Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis

Clinical Pharmacology &Therapeutics, EarlyView.
We evaluated whether concomitant 5‐aminosalicylic acid (5‐ASA) influences clinical remission in patients with ulcerative colitis (UC) receiving Janus kinase inhibitors (JAKi). In this retrospective, multicenter cohort study, UC patients receiving tofacitinib (n = 181), upadacitinib (n = 313), or filgotinib (n = 139) were included.
Antonio Tursi, Andrea Pasta, Walter Elisei, Brigida Barberio, Giammarco Mocci, Giovanni Maconi, Antonietta Gerarda Gravina, Raffaele Pellegrino, Giorgia Bodini, Edoardo Vincenzo Savarino, Alfredo Papa, Italian Network for Inflammatory Bowel Diseases (IN‐IBD), Davide G. Ribaldone, Antonio Ferronato, Greta Lorenzon, Davide Checchin, Francesca Lambroglia, Francesco Ferrara, Carla Felice, Giovanni Cataletti, Giorgia Bodini, Andrea Pasta, Giovanni Aragona, Patrizia Perazzo, Federica Gaiani, Stefano Kayali, Fabio Cortellini, Francesco Costa, Lorenzo Bertani, Antonella Scarcelli, Mariaelena Serio, Emanuele Bendia, Laura Bolognini, Daniele Balducci, Claudia Quatraccioni, Francesco Martini, Michele Montori, Simona Piergallini, Francesca Maria Onidi, Paolo Usai Satta, Giorgia Orrù, Raffaele Colucci, Francesco Bachetti, Gabrio Bassotti, Elisabetta Antonelli, Costantino Zampaletta, Giulia Rocco, Carlotta Sacchi, Franco Scaldaferri, Daniele Napolitano, Roberto Faggiani, Michela Di Fonzo, Rita Monterubbianesi, Cristiano Pagnini, Maria Giovanna Graziani, Maria Carla Di Paolo, Roberta Pica, Maddalena Zippi, Andrea Cocco, Claudio Cassieri, Roberto Lorenzetti, Gian Marco Giorgetti, Valeria Clemente, Patrizio Scarozza, Girolamo Bevevino, Giulia Zerboni, Federico Iacopini, Giacomo Forti, Laurino Grossi, Serafina Fiorella, Giovanni Lombardi, Marta Patturelli, Giuliana Vespere, Silvia Sedda, Vittorio D’Onofrio, Leonardo De Luca, Caterina Mucherino, Elvira D’Antonio, Laura Montesano, Pietro Capone, Guido Daniele Villani, Antonio Cuomo, Laura Donnarumma, Nicola Della Valle, Giuseppe Pranzo, Paolo Tonti, Viviana Neve, Libera Fanigliulo, Leonardo Allegretta, Alessia Immacolata Cazzato, Stefano Scorza, Manuela Marzo, Ileana Luppino, Francesco Luzza, Rocco Spagnuolo, Stefano Rodinò, Ladislava Sebkova, Antonio De Medici, Domenico Catarella, Dario D’Agostino, Elisabetta Di Bartolo   +100 more
wiley   +1 more source

Therapeutic role of methotrexate in pediatric Crohn’s disease

Biomolecules & Biomedicine, 2018
The main role of therapy in Crohn’s disease (CD) is to achieve long-term clinical remission, and to allow for normal growth and development of children.
Zlatko Djurić, Ljiljana Šaranac, Ivana Budić, Voja Pavlović, Jelena Djordjević   +4 more
doaj   +1 more source

Effectiveness and safety of ustekinumab in pediatric Crohn's disease: Results of the REALITI study

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Few approved treatments exist for children with Crohn's disease (CD). The REALITI study retrospectively assessed the effectiveness and safety of ustekinumab in real‐world clinical settings for children with CD. Methods Data were collected from the prospective ImproveCareNow (ICN) registry for pediatric patients (≥ 2 to <18 years old)
Steven J. Steiner, Jeremy Adler, Shehzad A. Saeed, Richard S. Strauss, Kristin M. Howe, Anna Sheahan, Renping Zhang, Kimberly R. Keihn, Katharine Harrow, Kelly K. Olano, David A. Evans, Kim Hung Lo, Nanhua Zhang, Lilianne Kim, Richard B. Colletti, Sheri Volger, for the ImproveCareNow Learning Health Network, Sabina Ali, Rana Ammoury, Keren L. Appel, Travis Ayers, Howard Baron, Julie Bass, Rachel Bensen, Erica J. Brenner, José Cabrera, Mallory Chavannes, J Fernando del Rosario, Jill Dorsey, Dana M. H. Dykes, Dawn R. Ebach, Bhaskar Gurram, Dyer Heintz, Leslie M. Higuchi, Edward J. Hoffenberg, Jeannie S. Huang, Esther Jacobowitz Israel, Traci W. Jester, Ian Kang, Ian Leibowitz, Tiffany Linville, Ross M. Maltz, Craig A. McKinney, Lybil B. Mendoza Alvarez, Phillip Minar, Tina Morhardt, Alisa J Muñiz Crim, Barbara Joanna Niklinska‐Schirtz, Daniel M. O'Connell, Helen Pappa, Brad Pasternak, Trusha Patel, Meryl K. Perlman, Kelly C. Sandberg, Marc E. Schaefer, Robbyn E. Sockolow, David L. Suskind, Gitit Tomer, Jeanne Tung, Amanda A. Wenzel, Denise D. Young   +60 more
wiley   +1 more source

Resolution of Levodopa/Dopa‐Decarboxylase Inhibitor—Associated Microscopic Colitis with Subcutaneous Foslevodopa/Foscarbidopa: A Case Series and Review of the Literature

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Microscopic colitis (MC) typically presents with chronic, non‐bloody watery diarrhea. Diagnosis requires endoscopy with colonic mucosal biopsies. The etiology is multifactorial, with several medications implicated, although only a few cases have been attributed to oral levodopa/dopa‐decarboxylase inhibitor (LDDCI) therapy.
Romana Hintner, Franziska Eberhardt, Manuela Kofler, Andreas Eigentler, Atbin Djamshidian, Florian Krismer, Anton Hittmair, Heinz Zoller, Valentina Ellinger, Beatrice Heim, Klaus Seppi   +10 more
wiley   +1 more source